These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26261848)

  • 1. Nintedanib in idiopathic pulmonary fibrosis.
    Woodcock HV; Maher TM
    Drugs Today (Barc); 2015 Jun; 51(6):345-56. PubMed ID: 26261848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
    Woodcock HV; Molyneaux PL; Maher TM
    Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
    Dimitroulis IA
    Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
    Bonella F; Stowasser S; Wollin L
    Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
    Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
    Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nintedanib for Idiopathic Pulmonary Fibrosis.
    Tepede A; Yogaratnam D
    J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
    Schmid U; Doege C; Dallinger C; Freiwald M
    Pulm Pharmacol Ther; 2018 Feb; 48():136-143. PubMed ID: 29133080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
    Keating GM
    Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
    Rodríguez-Portal JA
    Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib.
    Wind S; Schmid U; Freiwald M; Marzin K; Lotz R; Ebner T; Stopfer P; Dallinger C
    Clin Pharmacokinet; 2019 Sep; 58(9):1131-1147. PubMed ID: 31016670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
    Fukihara J; Kondoh Y
    Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib - efficacy, safety and practical aspects of treatment for patients with idiopathic pulmonary fibrosis.
    Martusewicz-Boros M; Górska K
    Adv Respir Med; 2020; 88(6):599-607. PubMed ID: 33393653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
    Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
    Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.
    Grimminger F; Günther A; Vancheri C
    Eur Respir J; 2015 May; 45(5):1426-33. PubMed ID: 25745048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of the tyrosine kinase inhibitor nintedanib.
    Ameri P; Tini G; Spallarossa P; Mercurio V; Tocchetti CG; Porto I
    Br J Clin Pharmacol; 2021 Oct; 87(10):3690-3698. PubMed ID: 33620103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nintedanib-induced glomerular microangiopathy: a case report.
    Hasegawa M; Uehara A; Suzuki T; Sekine R; Yazawa M; Ichikawa D; Koike J; Shibagaki Y
    CEN Case Rep; 2020 Nov; 9(4):295-300. PubMed ID: 32279192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.